Blueprint Medicines Stock Forecast - Triple Exponential Smoothing

BPMC Stock  USD 97.57  0.95  0.98%   
The Triple Exponential Smoothing forecasted value of Blueprint Medicines Corp on the next trading day is expected to be 97.92 with a mean absolute deviation of 1.87 and the sum of the absolute errors of 110.46. Blueprint Stock Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast Blueprint Medicines stock prices and determine the direction of Blueprint Medicines Corp's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of Blueprint Medicines' historical fundamentals, such as revenue growth or operating cash flow patterns.
  
The current year's Inventory Turnover is expected to grow to 0.63, whereas Payables Turnover is forecasted to decline to 2.58. . As of November 22, 2024, Common Stock Shares Outstanding is expected to decline to about 43.6 M. The current year's Net Loss is expected to grow to about (476.7 M).
Triple exponential smoothing for Blueprint Medicines - also known as the Winters method - is a refinement of the popular double exponential smoothing model with the addition of periodicity (seasonality) component. Simple exponential smoothing technique works best with data where there are no trend or seasonality components to the data. When Blueprint Medicines prices exhibit either an increasing or decreasing trend over time, simple exponential smoothing forecasts tend to lag behind observations. Double exponential smoothing is designed to address this type of data series by taking into account any trend in Blueprint Medicines price movement. However, neither of these exponential smoothing models address any seasonality of Blueprint Medicines Corp.

Blueprint Medicines Triple Exponential Smoothing Price Forecast For the 23rd of November

Given 90 days horizon, the Triple Exponential Smoothing forecasted value of Blueprint Medicines Corp on the next trading day is expected to be 97.92 with a mean absolute deviation of 1.87, mean absolute percentage error of 6.52, and the sum of the absolute errors of 110.46.
Please note that although there have been many attempts to predict Blueprint Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Blueprint Medicines' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).

Blueprint Medicines Stock Forecast Pattern

Backtest Blueprint MedicinesBlueprint Medicines Price PredictionBuy or Sell Advice 

Blueprint Medicines Forecasted Value

In the context of forecasting Blueprint Medicines' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Blueprint Medicines' downside and upside margins for the forecasting period are 95.35 and 100.48, respectively. We have considered Blueprint Medicines' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Market Value
97.57
97.92
Expected Value
100.48
Upside

Model Predictive Factors

The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Blueprint Medicines stock data series using in forecasting. Note that when a statistical model is used to represent Blueprint Medicines stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.
AICAkaike Information CriteriaHuge
BiasArithmetic mean of the errors 0.2646
MADMean absolute deviation1.8721
MAPEMean absolute percentage error0.0208
SAESum of the absolute errors110.4558
As with simple exponential smoothing, in triple exponential smoothing models past Blueprint Medicines observations are given exponentially smaller weights as the observations get older. In other words, recent observations are given relatively more weight in forecasting than the older Blueprint Medicines Corp observations.

Predictive Modules for Blueprint Medicines

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Blueprint Medicines Corp. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
94.0596.6299.19
Details
Intrinsic
Valuation
LowRealHigh
91.7194.2896.85
Details
Bollinger
Band Projection (param)
LowMiddleHigh
79.9692.16104.37
Details
20 Analysts
Consensus
LowTargetHigh
67.9374.6582.86
Details

Other Forecasting Options for Blueprint Medicines

For every potential investor in Blueprint, whether a beginner or expert, Blueprint Medicines' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Blueprint Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Blueprint. Basic forecasting techniques help filter out the noise by identifying Blueprint Medicines' price trends.

Blueprint Medicines Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Blueprint Medicines stock to make a market-neutral strategy. Peer analysis of Blueprint Medicines could also be used in its relative valuation, which is a method of valuing Blueprint Medicines by comparing valuation metrics with similar companies.
 Risk & Return  Correlation

Blueprint Medicines Corp Technical and Predictive Analytics

The stock market is financially volatile. Despite the volatility, there exist limitless possibilities of gaining profits and building passive income portfolios. With the complexity of Blueprint Medicines' price movements, a comprehensive understanding of forecasting methods that an investor can rely on to make the right move is invaluable. These methods predict trends that assist an investor in predicting the movement of Blueprint Medicines' current price.

Blueprint Medicines Market Strength Events

Market strength indicators help investors to evaluate how Blueprint Medicines stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Blueprint Medicines shares will generate the highest return on investment. By undertsting and applying Blueprint Medicines stock market strength indicators, traders can identify Blueprint Medicines Corp entry and exit signals to maximize returns.

Blueprint Medicines Risk Indicators

The analysis of Blueprint Medicines' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Blueprint Medicines' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting blueprint stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:
Check out Historical Fundamental Analysis of Blueprint Medicines to cross-verify your projections.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.09)
Revenue Per Share
6.986
Quarterly Revenue Growth
1.266
Return On Assets
(0.15)
Return On Equity
(0.50)
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.